The Altered Vascular Reparation in Heart Failure: 
the Controversial Role of Endothelial Progenitor Cell Dysfunction

Alexander E. Berezin
Consultant of Therapeutic Unit, Private Hospital “Vita-Center”
Zaporozhye, Ukraine
&
Consultant of Therapeutic Unit, Department of Internal Medicine
Medical University, Zaporozhye, Ukraine

Copyright © 2017 Alexander E. Berezin. This article is distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Heart failure (HF) remains a leading factor of premature mortality among patients with established cardiovascular disease worldwide. Altered vascular reparation is considered a central player in abnormalities of vascular tone, endothelial dysfunction, thrombosis, coagulation, which contribute to pathogenesis of HF. The endothelial progenitor cells (EPCs) are endothelial cell precursors with innate angiopoetic activity and an ability to promote collateral vessel formation and restore endothelial function. Consequently, EPC dysfunction was described as a phenomenon associated with decreased number and poor function of circulating EPCs. Recent clinical studies have shown that the EPC dysfunction may really be an early indicator of poor prognosis in patients with HF, especially in HF individuals with preserved ejection fraction. The Editorial is depicted the promising role of EPC dysfunction in stratification of the patients at risk of HF and reflects several unresolved controversies among this issue.

Keywords: heart failure; endothelium; reparation; progenitor endothelial cells; biomarkers; outcomes
Introduction

Development and progression of heart failure (HF) strongly relates to microvasculature damage, endothelium dysfunction and target organ perfusion abnormalities [1]. The conceptual molecular mechanisms of shaping vascular wall cell injury base on an opinion regarding an imbalance between a damage of target cells and prevention or restore of altered structure and impaired function of them [2]. The central player in mediating vascular tissue reparation is endogenous regenerative capacity of residential cells with pluripotent activity and predominantly originated from bone-marrow stem cells and rarely from peripheral stem cells [3].

The endothelial progenitor cells (EPCs) are endothelial cell precursors with innate angiopoetic activity and an ability to promote collateral vessel formation and restore endothelial function [4]. EPCs are not only involved in the repair of the vascular wall and supporting functionality of endothelium, but they are able to release micro vesicles (MVs) with wide range of biological active substrates, i.e. active molecules, proteins, hormones, growth factors, micro-RNAs, DNAs [5, 6]. All these factors that transferred by MVs were found a component of endogenous endothelial repair system that contributes in a regulation of basic capabilities of EPCs, i.e. mobbing, differentiation, proliferation, migration, apoptosis and survival [7, 8]. There is a large body of evidence regarding that the pro- and anti-inflammatory cytokines produced by numerous immune and antigen-presenting cells in HF are co-regulators of EPC activities through supporting oxidative stress and via direct stimulation of some intracellular signal systems (Akt/STAT3) [9, 10]. Moreover, traditional cardiovascular (CV) risk factors especially diabetes mellitus, smoking and dyslipidemia may negatively influence on functionality and number of circulating EPCs [11, 12]. However, poor abilities of EPCs to differentiation, migration, transformation, survival, as well as lowered number of circulating EPVs in peripheral blood in individuals at risk of HF and among patients with established HF with different phenotypes were determined in numerous studies [13-18]. Finally the predictive and diagnostic role of EPC count and function in HF is not fully clear and requires to be reappraised in the future. The aim of the editorial is to summarize the knowledge regarding

The definition of the EPCs

Notably, an attribute of a progenitor cells population is ability of them to self-renewal and multiple potentialities [18]. Sorting and identification of EPC populations, i.e. hematopoietic progenitor cells, circulating endothelial cells, and culture-generated outgrowth endothelial cells, based on immunophenotyping of surface antigens that belong to various cell lines [19]. Using CD45, CD34, CD133, VEGFR (vascular endothelial growth factor receptor-2)+ EPC can be differentiated from other cell lines, while CD34+ progenitor mononuclear cells can express on the surface the same endothelial antigens [20]. Therefore, there is a subset of circulating EPCs, which is capable of in vitro differentiating into outgrowth endothelial cells with vascular regeneration abilities [21]. Interestingly,
circulating endothelial cells do not belong to the cells with angiopoetic features, because they are resulting in apoptosis or cell damage [22]. However, there is a limited fraction of circulating endothelial cells that may belong to endothelial precursors, but does not express appropriate surface antigens, which allow differentiating them from mature endothelial cells using FACS protocol by flow cytometry [23]. Therefore, populations of EPCs may distinct from the hematopoietic cell lineages by endothelial cell colony shaping. Practically, CD45-, CD31+, CD144+, and VEGFR+ are the widely used characteristics that characterize EPCs. Probably CD133 would be another antigen that could help differentiating EPCs from others, while there is no consensus of the experts regarding that. Finally, despite there is no final ultimate definition of immune phenotype of endothelial precursors, EPCs are frequently defined as CD45-CD31+CD144+VEGFR+ cells that contribute to neovascularization and angiogenesis directly or by secreting wide range spectrum of proangiogenic factors [15, 24].

The definition of EPC dysfunction

EPC dysfunction was described as a phenomenon associated with decreased number and poor function of circulating EPCs [3]. Recent clinical studies have shown that the EPCs was strongly related to metabolic co-morbidities and appeared in resulting in epigenetic modification of precursors [11]. There is the suggestion that the metabolic memory phenomenon that was recently described in diabetes mellitus and even in prediabetes is a result of EPC dysfunction [13]. Moreover, variability of glycated hemoglobin at early stages of diabetes mellitus development and insulin resistance are well established factors contributing to lowered number and poor function of EPCs in peripheral blood. Probably, EPC dysfunction reflects exhausted repair capability of endogenous vascular repair potency and directly mediates microvascular abnormalities including endothelial dysfunction. Nevertheless, EPC dysfunction was recently determined in HF individuals in numerous clinical and observational studies [14-17]. All these facts allow grasping the EPC dysfunction in certain extent a central player in pathogenesis of HF in relation to metabolic comorbidities.

EPC dysfunction and HF-related outcomes

Recent clinical trials have shown that EPC count was a significant and independent inverse predictor of CV mortality, newly diagnosed HF and HF-related outcomes [25-27]. However, there are several controversies affecting immune phenotypes of EPCs and its role in prediction of HF-related events. The first controversy based on evidence regarding that the number of circulating EPCs labeled CD34+VEGF+ were found independent predictors of mortality rate in Hfpef patients [28]. Second controversy affects that the deficiency of CD45dimCD34+VEGFR+ EPCs rather associated with Hfpef than HFref [16].
Third controversy reflects lack of sufficient association between the number of circulating EPCs with different immune phenotypes (CD45dimCD34+VEGFR+ and CD45dimCD34+VEGFR+Tie2+) and traditional CV risk factors [29, 30], while the decreased number and lowered function of EPCs were found in patients with diabetes mellitus, abdominal obesity, and insulin resistance [31, 32]. On the other hand, there is evidence that the natriuretic peptide plasma levels, left ventricular ejection fraction, and NYHA class of HF were known as strong predictors for depletion of CD45dimCD34+VEGFR2+ EPC count [33]. Whether EPC dysfunction associated with decreased number and lowered function of EPCs appears prior to HF in direct link with CV risk factors or in contrast this phenomenon is essential for HF development and advance is not fully understood and requires to be investigated in details in the future.

In conclusion, taking into consideration the role of circulating EPCs in endogenous repair of impaired endothelial structure and function, deficiency of EPCs with pro-angiogenic phenotypes remains to be promising predictors of CV mortality and HF-related outcomes.

**Funding and grants:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interests:** none declared

**References**


Heart failure and progenitor endothelial cell dysfunction


Received: October 1, 2017; Published: October 18, 2017